Last reviewed · How we verify

switch NPH to glargin

Les Laboratoires des Médicaments Stériles · FDA-approved active Small molecule ✓ Verified May 2026

switch NPH to glargin is a Long-acting basal insulin analog Small molecule drug developed by Les Laboratoires des Médicaments Stériles. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production.

Glargine, a small molecule insulin, has been studied as a potential replacement for NPH insulin in the treatment of Diabetes Mellitus. A clinical trial (NCT06999551) compared the efficacy and safety of glargine to NPH insulin in diabetic patients.

At a glance

Generic nameswitch NPH to glargin
SponsorLes Laboratoires des Médicaments Stériles
Drug classLong-acting basal insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin glargine is a recombinant human insulin analog modified to have a prolonged duration of action (up to 24 hours). It binds to the insulin receptor on target cells, facilitating glucose transport into muscle and adipose tissue while inhibiting gluconeogenesis and glycogenolysis in the liver. This switch from NPH (neutral protamine Hagedorn) insulin represents a transition from an intermediate-acting to a long-acting basal insulin formulation.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about switch NPH to glargin

What is switch NPH to glargin?

switch NPH to glargin is a Long-acting basal insulin analog drug developed by Les Laboratoires des Médicaments Stériles, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does switch NPH to glargin work?

Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production.

What is switch NPH to glargin used for?

switch NPH to glargin is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes switch NPH to glargin?

switch NPH to glargin is developed and marketed by Les Laboratoires des Médicaments Stériles (see full Les Laboratoires des Médicaments Stériles pipeline at /company/les-laboratoires-des-m-dicaments-st-riles).

What drug class is switch NPH to glargin in?

switch NPH to glargin belongs to the Long-acting basal insulin analog class. See all Long-acting basal insulin analog drugs at /class/long-acting-basal-insulin-analog.

What development phase is switch NPH to glargin in?

switch NPH to glargin is FDA-approved (marketed).

What are the side effects of switch NPH to glargin?

Common side effects of switch NPH to glargin include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does switch NPH to glargin target?

switch NPH to glargin targets Insulin receptor and is a Long-acting basal insulin analog.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing